<DOC>
	<DOCNO>NCT00757783</DOCNO>
	<brief_summary>The purpose research study compare change triglyceride lipid ( level fat found blood ) Baseline ( Day 1 ) Week 12 darunavir/ritonavir 800/100 mg daily versus atazanavir/ritonavir 300/100 mg daily combination fixed-dose background regimen consist emtricitabine [ FTC ] /tenofovir [ TDF ] 200/300 mg daily ) . This study also evaluate safety ( adverse event ) , effectiveness , tolerability darunavir/ritonavir atazanivir/ritonavir 48 week .</brief_summary>
	<brief_title>Changes Triglyceride Other Lipids ( Levels Fats Found Blood ) When Taking Darunavir Compared Atazanavir HIV-infected Patients That Have Never Received Treatment</brief_title>
	<detailed_description>The purpose study expand understand metabolic effect darunavir/ritonavir ( DRV/r ) HIV-infected patient . This phase 4 , multicenter , open-label , randomize ( study drug assign chance ) , comparative study design compare change lipid , glucose , insulin parameter HIV-infected , anti-retroviral ( ARV ) naive patient treat DRV/r 800/100 mg daily ( QD ) versus atazanavir/ritonavir ( ATV/r ) 300/100 mg QD combination common background emtricitabine ( FTC ) / tenofovir ( TDF ) 200/300 mg QD . In addition , change inflammatory marker measure . A substudy parent study TMC114HIV4023 evaluate insulin sensitivity endothelial function subset patient . The study conduct approximately 16 study site United States . Approximately 60 HIV-1 infected , treatment-naive adult patient enrol study . Screening take place 4-week period . At baseline visit , eligible patient randomize 1:1 ratio receive DRV/r 800/100 mg QD ATV/r 300/100 mg QD administer combination fixed-dose background regimen consist emtricitabine ( FTC ) /tenofovir ( TDF ) 200/300 mg daily . The treatment period 48 week . Study assessment perform clinic visit end week 4 , 8 , 12 , 24 , 36 , 48 . The primary endpoint assess week 12 . All patient return follow visit 1 week 4 week completion study treatment . During treatment period , patient see regular visit investigator assess patient 's medical condition , Adverse Events study drug compliance . Laboratory evaluation efficacy safety do regular visit well blood pressure monitoring . Up twenty patient ( evenly randomize receive DRV/r ATV/r ) meet additional entry criterion enrol substudy . The study hypothesis change triglyceride lipid baseline week 12 similar DRV/r arm versus ATV/r arm . The substudy hypothesis DRV/r adversely affect insulin sensitivity endothelial function 12 week therapy , change baseline insulin sensitivity endothelial function similar DRV/r arm versus ATV/r arm . During treatment period , patient see regular visit investigator assess patient 's medical condition , Adverse Events study drug compliance . Laboratory evaluation efficacy safety do regular visit well blood pressure monitoring . Patients randomize 1:1 ratio receive darunavir/ritonavir 800/100 mg daily ( QD ) plus emtricitabine ( FTC ) /tenofovir ( TDF ) 200/300 mg QD atazanavir/ritonavir 300/100 mg QD plus emtricitabine ( FTC ) /tenofovir ( TDF ) 48 week .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV1 RNA 1000 copies/mL No previous treatment antiretroviral drug 10 day Demonstrated sensitivity [ Fold Change ( FC ) = low Clinical Cut Off ( CCO ) ] tenofovir , darunavir atazanavir Demonstrated sensitivity emtricitabine define absence M184V/I mutation Any CD4 ( Cluster Differentiation 4 ) cell count Body mass index &gt; 30 kg/m2 Laboratory parameter follow : fasting glucose &gt; 110 mg/dL , LowDensity Lipoprotein ( LDL ) cholesterol &gt; 130 mg/dL , triglycerides &gt; 200 mg/dL Presence currently active AIDSdefining illness Treatment primary HIV infection postexposure prophylaxis HIV Patients acute chronic hepatitis A , B C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Immunodeficiency Virus , Human</keyword>
	<keyword>PREZISTA</keyword>
	<keyword>darunavir</keyword>
	<keyword>TMC114</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Truvada</keyword>
	<keyword>Atazanavir</keyword>
	<keyword>REYATAZ</keyword>
	<keyword>HIV Infections</keyword>
	<keyword>Treatment Na√Øve</keyword>
</DOC>